Consistent with the goals ofthe Rare Diseases Clinical Research Network (RDCRN), the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Clinical Research Projects for Observational/Longitudinal Studies or Clinical Trials have been developed in joint partnership with patient advocacy groups (PAGs) with the objective of answering immediately important questions concerning the rare diseases eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC).
We aim to 1) better define the diagnostic and clinical features of these diseases (Project 1);2) determine whether the level of tissue eosinophils, a parameter that is currently required for disease diagnosis, is an adequate measurement of clinical outcome as it has so far been assumed that the level reflects disease severity and adverse prognosis (Project 1);3) develop validated clinical outcome metrics (COMs) that can be used to quantitatively monitor disease (Project 1);4) identify and refine biomarkers on the basis of novel approaches that take advantage of direct procurement of readily accessible diseased tissue that will be subjected to whole-genome transcriptome profiling (Project 1 and Project 2);5) conduct a clinical trial that optimizes therapy for the most common of these diseases (EoE) on the basis of currently available approaches - dietary elimination diets and glucocorticoids (Project 2);and 6) develop a personalized and predictive medicine approach to understanding and treating these diseases (Project 1 and Project 2).
The proposed clinical research projects have been developed in partnership with patient advocacy groups with the objective of answering immediately important questions concerning the understanding and treatment ofthe rare diseases eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis. These diseases are painful, lifelong diseases that make it difficult or impossible for individuals to eat many or all foods.
|Durrani, Sandy R; Mukkada, Vincent A; Guilbert, Theresa W (2018) Eosinophilic Esophagitis: an Important Comorbid Condition of Asthma? Clin Rev Allergy Immunol 55:56-64|
|Rochman, Mark; Azouz, Nurit P; Rothenberg, Marc E (2018) Epithelial origin of eosinophilic esophagitis. J Allergy Clin Immunol 142:10-23|
|Philpott, Hamish; Dellon, Evan (2018) Histologic improvement after 6 weeks of dietary elimination for eosinophilic esophagitis may be insufficient to determine efficacy. Asia Pac Allergy 8:e20|
|Fahey, Lisa M; Chandramouleeswaran, Prasanna M; Guan, Shaobo et al. (2018) Food allergen triggers are increased in children with the TSLP risk allele and eosinophilic esophagitis. Clin Transl Gastroenterol 9:139|
|Wechsler, Joshua B; Bolton, Scott M; Amsden, Katie et al. (2018) Eosinophilic Esophagitis Reference Score Accurately Identifies Disease Activity and Treatment Effects in Children. Clin Gastroenterol Hepatol 16:1056-1063|
|Pesek, Robert D; Gupta, Sandeep K (2018) Emerging drugs for eosinophilic esophagitis. Expert Opin Emerg Drugs 23:173-183|
|Spergel, Jonathan M; Aceves, Seema S; Kliewer, Kara et al. (2018) New developments in patients with eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERS Symposium at the 2018 American Academy of Allergy, Asthma & Immunology Meeting. J Allergy Clin Immunol 142:48-53|
|Schwartz, Justin T; Morris, David W; Collins, Margaret H et al. (2018) Eosinophil progenitor levels correlate with tissue pathology in pediatric eosinophilic esophagitis. J Allergy Clin Immunol :|
|Mark, Jacob; Fernando, Shahan D; Masterson, Joanne C et al. (2018) Clinical Implications of Pediatric Colonic Eosinophilia. J Pediatr Gastroenterol Nutr 66:760-766|
|Nguyen, N; Fernando, S D; Biette, K A et al. (2018) TGF-?1 alters esophageal epithelial barrier function by attenuation of claudin-7 in eosinophilic esophagitis. Mucosal Immunol 11:415-426|
Showing the most recent 10 out of 103 publications